MOTS-c

1. Identity

INN: None assigned by WHO; MOTS-c is not a USAN/INN-named therapeutic Aliases / FDA spelling: MOTSc, MOTS-C, “MOTs-C” (FDA PCAC agenda spelling) [Regulatory document — FDA Advisory Committee Calendar, Docket FDA-2025-N-6895] Sequence (1-letter): MRWQEMGYIFYPRKLR (16 aa) [Peer-reviewed human study — Lee 2015 PMID 25738459] 🔴 Molecular formula / weight: C₁₀₂H₁₅₅N₂₉O₂₂S₂ free base; ~2,174 Da CAS: No assigned CAS for the native 16-aa peptide as of 2026-05-14 — vendor-circulating numbers (e.g. 1627580-64-6) are unverified Class: Mitochondrial-derived peptide (MDP); subcategory mitokine. Encoded within a short ORF inside the mitochondrial 12S rRNA gene (MT-RNR1) [Peer-reviewed human study — Lee 2015 PMID 25738459] Investigational analog: CB4211 (CohBar synthetic analog; program discontinued 2023) ⚠️ Brand names: None — no approved product exists in any jurisdiction.

2. History and Development

Humanin, the first mitochondrial-encoded bioactive peptide, was identified in 2001. MOTS-c was identified in 2015 by Lee, Cohen and colleagues at USC, published in Cell Metabolism (Lee 2015, PMID 25738459) [Peer-reviewed human study — Lee 2015]. The discovery laboratory founded CohBar, Inc. (2007) to commercialise MDPs; CB4211 was selected as lead candidate for NASH/obesity, entered Phase 1a in 2019 and Phase 1b in obese NAFLD subjects (n = 20) completed April 2021 ⚠️. Positive topline announced 10 August 2021 (no peer-reviewed publication) ⚠️. The CohBar program ended in 2023: reverse-merger with Morphogenesis terminated 1 November 2023, board determined no viable path forward, company dissolved [Regulatory document — CohBar 8-K filed 2023-11-01, SEC]. No successor sponsor has continued CB4211 or native MOTS-c clinical development as of 14 May 2026. Independent academic work continued (USC remains dominant 🔴; secondary groups in China, Japan, Qatar, New Zealand, Korea).

3. Mechanism of Action

Demonstrated (human). Endogenous MOTS-c is detectable in human serum/plasma and skeletal muscle by ELISA and Western blot using Cohen-laboratory antibodies 🔴 [Peer-reviewed human study — Lee 2015; Reynolds 2021 PMID 33473109]. Acute exercise raises circulating MOTS-c (~1.5× plasma, ~11.9× skeletal-muscle Western) in a small cohort (n = 10, Reynolds 2021 🔴). Circulating MOTS-c declines with age and is lower in T2D, obesity, NAFLD, PCOS, gestational diabetes — all observational [Peer-reviewed human study — multiple cohorts; Wrzosek 2023 PMID 37958833]. The Asian-specific m.1382A>C polymorphism (K14Q substitution) modifies T2D risk and exercise-capacity association in Japanese / Japanese-American cohorts [Peer-reviewed human study — Zempo/Kumagai/Cohen 2021 PMID 33468709]; replication outside East Asian populations is structurally limited (variant largely absent elsewhere).

No direct in-human evidence of nuclear translocation, AMPK binding, CK2 binding, or downstream gene-regulation by exogenous MOTS-c has been published as of 14 May 2026. All such mechanistic claims remain preclinical.

Proposed / preclinical (status: preclinical).

• AMPK pathway activation in skeletal muscle, adipose, bone-resident cells [Lee 2015; Ming 2016 PMID 27237975]
• Folate-AICAR / methionine-one-carbon cycle as indirect AMPK route [Lee 2015 🔴]
• CK2 direct binding in skeletal muscle — proximal target proposed 2024 [Kumagai/Cohen 2024 PMID 39561759 🔴]
• Mitonuclear retrograde signalling and nuclear translocation under metabolic stress [Kim/Mehta/Cohen 2018 PMID 29983246 🔴]
• TRIM72 / membrane repair (AMPK-independent) [Jia 2024 PMID 39239515 — independent Chinese group]
• ROS-CK2A-MYH9 axis in lung ischaemia-reperfusion [Nanjing Medical University group 2025 — independent]

Status: proximal molecular target unresolved. AMPK vs CK2 vs TRIM72 — the literature has not converged. Cellular uptake mechanism for exogenously administered cationic 16-aa peptide is not characterised.

4. Regulatory Status

4.1 Drug-regulatory status by jurisdiction

Authority	Status (2026-05-14)	Source
FDA (US)	Not approved. No NDA, no BLA, no orphan designation. 503A bulks list: placed on Category 2 in 2023 (significant safety concerns / not eligible); removed from Category 2 effective ~22 April 2026 following HHS Secretary withdrawal of safety-concern nominations (12-peptide cohort); removal did not confer Category 1. PCAC review scheduled 23–24 July 2026 for inclusion on 503A bulks list; FDA-evaluated uses: “Obesity and osteoporosis”; Docket FDA-2025-N-6895 (comments due 9 July 2026).	[Regulatory document — FDA Drugs@FDA queried 2026-05-14; FDA Advisory Committee Calendar]
EMA (EU)	Not approved. No EPAR, no orphan.	[Regulatory document — EMA database]
MHRA / TGA / Health Canada / PMDA / NMPA / MFDS / GRLS	Not approved in any.	[Regulatory documents — respective databases, queried 2026-05-14]
WHO EML / EMLc	Not listed.	[WHO Model List 2025]

4.2 Anti-doping status

Authority	Status
WADA 2026 Prohibited List	Prohibited at all times (in- and out-of-competition) under S4.4.1 Activators of AMP-activated protein kinase (AMPK). MOTS-c is explicitly cited by USADA as falling under S4.4.1. Category-level S0 (Non-Approved Substances) also applies by virtue of no approved human therapeutic use anywhere. [Anti-doping authority — WADA 2026 Prohibited List; USADA “What is the MOTS-c peptide?”]
WADA Monitoring Program 2026	Not on Monitoring Program (because already on Prohibited List).
TUE eligibility	Not available. USADA explicitly states no TUE basis exists: no approved indication, no medical-necessity argument, substance is experimental. [Anti-doping authority — USADA athlete advisory]
NCAA Banned Drug Classes 2025–26	Captured under “peptide hormones, growth factors and related substances” and “anti-estrogens and other hormone and metabolic modulators.”
DoD-OPSS Prohibited Dietary Supplement Ingredients	Listed as high-risk; not a legitimate dietary supplement ingredient (unapproved drug).
Global DRO	Returns prohibited-at-all-times per S4.4.1. Check date: 2026-05-14.
BSCG advisory (April 2026)	Flags MOTS-c as part of the peptide cohort under PCAC review; experimental, not approved, athlete-prohibited.
Detection window	Knoop & Thevis 2019 (German Sport University Cologne) validated an LC/MS assay that detected synthetic MOTS-c spiked into plasma at 100 pg/mL but failed to detect endogenous circulating MOTS-c in unspiked human plasma; doping-control analytical reliability for unspiked samples remains a methodological dispute (see 7.5). [Peer-reviewed human study — Knoop & Thevis 2019 PMID 30394592]
Notable sanctions / precedents	No named athlete sanction tied specifically to MOTS-c identified in this pass.

Last regulatory review: 2026-05-14.

5. Formulations and Routes

• CB4211 (clinical investigational analog): 25 mg subcutaneous once daily × 4 weeks (Phase 1b regimen, n = 20) ⚠️. Study parameter; not a recommendation.
• Native MOTS-c (preclinical and “research chemical”): Preclinical IP injection in rodents at 0.5–15 mg/kg/day (5 mg/kg/day commonly cited). Lyophilised synthetic 16-aa peptide widely sold in 5–10 mg, 20 mg, and 40 mg vials for SC/IM reconstitution; intranasal and pre-mixed-pen formats marketed. None FDA-approved, no USP/EP/BP/JP monograph, no cGMP human-use manufacturing.

6. Preclinical Evidence

• Metabolic / T2D: Daily IP MOTS-c (≈5 mg/kg) prevented HFD-induced obesity, improved glucose tolerance, reversed age-dependent insulin resistance in 28-mo C57BL/6 mice [Lee 2015 🔴]. K14Q variant lacks function in HFD males [Zempo/Kumagai 2021]. CK2 direct binding identified 2024 [Kumagai/Cohen 2024 🔴].
• Obesity/NAFLD-NASH: CB4211 reduced hepatic steatosis, ALT/AST, body weight in DIO and MCD NASH models ⚠️ — basis for IND.
• Exercise capacity / sarcopenia: Systemic MOTS-c (15 mg/kg intermittent) increased treadmill performance across 2/12/22-month mice; late-life-initiated dosing improved physical capacity [Reynolds 2021 🔴]. TRIM72/sarcolemma trafficking [Jia 2024].
• Cardiovascular: Myocardial efficiency in trained rats [Yuan 2021 — Chengdu Sport University, independent]; cardioprotection in STZ-diabetic rats [Tang 2023]; lung ischaemia-reperfusion via ROS-CK2A-MYH9 [Nanjing 2025].
• Bone: MOTS-c (5 mg/kg/day × 12 wk) reduced bone loss in ovariectomised mice via AMPK [Ming 2016 — Fourth Military Medical University, independent].
• Sepsis / ALI: Improved survival in LPS-challenged mice [Miller 2020 PMID 32459448].

Single-group dependency 🔴: The largest mechanism-defining preclinical body (Lee 2015, Kim 2018, Reynolds 2021, Kumagai 2024) originates from or co-authors with the Cohen laboratory at USC. Several “independent” replications (e.g., Auckland Merry/Cameron-Smith group on Reynolds 2021) carry overlapping authorship. Truly independent groups (Fourth Military Medical, Chengdu, Nanjing, Tohoku, Hamad) work largely on indication-specific extension, not on the core mechanism claims.

7. Clinical Evidence

Cochrane SR: None on MOTS-c. None possible — there is only one completed interventional trial of any MOTS-c-class molecule.

Phase 1a/1b — CB4211 (CohBar, NCT04004273 cited in community sources; not currently active under that identifier) ⚠️

• Phase 1a: 65 healthy volunteers, SAD/MAD (7 d), multi-centre, randomised, double-blind, placebo-controlled.
• Phase 1b: 20 obese subjects with NAFLD (≥10% liver fat by MRI-PDFF), CB4211 25 mg SC daily × 4 wk vs placebo, residential, lead investigator Loomba (UCSD).
• Primary endpoint (met): Safety/tolerability — “well-tolerated, no SAEs”; only >10% AE was transient mild-to-moderate injection-site reactions ⚠️.
• Exploratory (press release, not peer-reviewed) ⚠️: ALT −21% vs placebo; AST −28%; fasting glucose −6%; body weight trend (NS); liver fat MRI-PDFF: −5.03% absolute CB4211 vs −4.88% placebo — no significant treatment effect on the imaging endpoint.
• Status: No Phase 2 initiated. AASLD November 2021 abstract/poster only ⚠️. Program ended with CohBar dissolution 2023.

Native 16-aa MOTS-c: No interventional human trial registered on any major registry as of 14 May 2026.

Observational human studies (endogenous biomarker, NOT intervention): Lower circulating MOTS-c reported in T2D, obesity, NAFLD, PCOS, sarcopenia (mixed across cohorts) — methodological reliability disputed (see 7.5). Higher skeletal-muscle MOTS-c correlates with healthier myofibre composition in older men [D’Souza 2020 PMID 32218446]. Exercise-RCT secondary analyses (Dieli-Conwright 2021 PMID 34413414) show MOTS-c modulation by exercise intervention. No observational study involves administration of exogenous MOTS-c.

Longevity / anti-aging clinical interpretation. No interventional human longevity trial of MOTS-c. The “anti-aging” framing rests on (a) the m.1382A>C centenarian association in Japanese cohorts (genetic, not interventional) and (b) preclinical late-life-initiated mouse data (Reynolds 2021 🔴). Causal human evidence: absent.

7.5 Disputed Claims

Four substantive published disputes as of 2026-05-14:

1. ELISA vs LC/MS validity for circulating MOTS-c. Knoop & Thevis 2019 (WADA-validated assay) detected spiked synthetic MOTS-c at 100 pg/mL but failed to detect endogenous circulating MOTS-c in unspiked plasma, despite parallel commercial ELISA returning quantifiable values. A 2024 review corrigendum [PMC10963594] explicitly retracted a sentence calling LC/MS “gold-standard proof for MDP expression,” replacing it with the failure language. Implication: the body of observational “circulating MOTS-c level” literature may reflect antibody cross-reactivity rather than intact 16-aa peptide. Unresolved.

2. Functional translation vs sORF artifact. Gruschus 2023 [PMID 37644062] analysed synonymous codon bias across vertebrate mtDNA and found strong evolutionary conservation for humanin and SHLP6 but no significant codon bias for MOTS-c (along with SHLP1/2/3/5). The authors note MOTS-c “contains highly conserved N-terminal regions, and [its] biological importance cannot be ruled out.” Minority view: MDP sORFs including MOTS-c may be functional under specific stress conditions but not canonical regulated mitokines. The Lee laboratory contests this interpretation; unresolved.

3. Direct vs indirect AMPK activation. Original Lee 2015 proposal: folate-AICAR-mediated indirect activation 🔴. 2024 CK2-binding mechanism (Kumagai/Cohen 🔴) and 2024 TRIM72/membrane-repair pathway (Jia, AMPK-independent) suggest AMPK is one of several downstream consequences, not a single proximal mechanism. Not converged.

4. m.1382A>C “longevity SNP” framing partially refuted by originators. The initial Japanese-centenarian association (Fuku 2015, n = 96) was followed by an expanded analysis (Zempo/Kumagai 2021, n = 736) showing the polymorphism does not affect lifespan, although it affects T2D risk in males. Generalisation outside East Asian haplogroups is structurally precluded — variant largely absent elsewhere.

7B. Community Evidence Layer

Driving subcommunity (historical): Anti-aging/longevity biohackers first (Ben Greenfield 2019 “Wolverine Stack” anchor; Modern Healthspan Cohen interviews). Driving subcommunity (current): Bodybuilding fat-loss audience after Vigorous Steve’s 2025 “Safest & Best Mots-C Dosing Protocols” YouTube + “No-Stim Fat-Burner Stack” podcast (MOTS-c + SLU-PP-332 + methylene blue + cardarine ± GC-1). Third wave: GLP-1 stackers running MOTS-c with retatrutide / tirzepatide.

Trajectory: Rising. Three active MESO-Rx threads in 2026 (Mots-C / “5-Week Ramping Protocol” 48 replies / “MOTS-C & SS-31????” 51 replies in one week). Vendor breadth ≥15 sources. Not penetrated to mainstream longevity podcasting (no Huberman/Attia/Sinclair episode dedicated to MOTS-c).

Documented protocols — two competing schools:

• High-per-dose / low-frequency: 5–10 mg SC 1–2× weekly (Greenfield ≥10 mg cited in Boundless; community frequently questions if this is real or transcription error).
• Low-dose daily: 1–2 mg SC fasted pre-cardio (Hoiiysmoke, dayusmc, xelatothe; popularised post-Vigorous Steve deep-dive as the dominant 2026 protocol).
• Pre-fasted-cardio timing is the one near-universal heuristic. The published animal dose (~15 mg/kg) is non-translatable to humans by community consensus.

Top claimed effects (sourced):

• Subjective “clean” energy / reduced fatigue — widespread (Hoiiysmoke “crazy energy”; dayusmc replaced Nuvigil)
• Lower HR / improved fasted cardio — common (xelatothe Oura/Garmin data, May 2026) — most consistent convergent claim
• Fat loss / GLP-1 augmentation — common (Nattybynature 12 mg/wk + 3 mg retatrutide; atruse)
• Tachyphylaxis / effect tapers — common (atruse, Hoiiysmoke)
• “Felt nothing” / null effect — common (yoyoy, dallascowboys01, amazonas “like injecting straight up water”)

Reported side effects:

• Injection-site burning / red welts — widespread but user-variable
• Subcutaneous hematoma — occasional (dedicated MESO-Rx thread)
• Anaphylaxis warning (community-only signal) — Proud Pangolin’s “always keep an Epipen at hand” advisory (Feb 25 2026) widely repeated; no peer-reviewed clinical anaphylaxis report exists
• Acute “head spin” at single doses ≥5 mg — occasional (toofy)
• Post-pin lethargy / “methylation crash” theory — occasional (Sjwthai; Necessary Evil recommends methylfolate co-administration)
• Null effect is itself a common adverse-experience report driving vendor-quality skepticism

Community dissent:

• Placebo / hype critique: Stevemavrick, thejumpingsheep — “super hit or miss”; “peptides over-hyped because of GLP-1 success”
• AMPK-vs-mTOR tradeoff — Necessary Evil flags MOTS-c as “massive AMPK activator” opposing muscle protein synthesis; most sophisticated mechanism objection in circulation
• Vendor / purity skepticism — yoyoy “Janoshik tested but who the fuck knows”; Aminoclub publicly displays labeled 10 mg / actual 8.95 mg COA — the cleanest documented batch underdose
• BAC-water “myth” — ostrichsak corrects the widely-circulated 28-day degradation claim (the USP window is endotoxin-driven, not stability)

Stack patterns:

• MOTS-c + SS-31 (elamipretide) — dominant 2026 stack; entire MESO-Rx thread devoted to it
• MOTS-c + GLP-1 (retatrutide/tirzepatide) — fat-loss synergy positioning
• MOTS-c + NAD+/NMN/NR; + methylene blue + PQQ + CoQ10 — Vigorous Steve “mitochondrial stack”
• MOTS-c + 5-Amino-1MQ + NMN — Vigorous Steve “reaction” content
• MOTS-c + fasted cardio timing — universal pairing with the activity itself
• MOTS-c + methylfolate — community theoretical mitigation of folate-cycle effect (not universally adopted)

Vendor landscape: Peptide Sciences, Core Peptides, Limitless Life, BioLongevity Labs, Biotech Peptides, Aminoclub (publishes labeled-vs-actual COA), Verified Peptides, Peptide Partners, Apex, Modern Peptides, Amino Asylum, Pharma Lab Global (pre-mixed pen), Omegamino, Soma Chems, Amino Tech, Canadian Peptides, Disguised Alpha, Anabolic Pharmacist. Observed price range: $3.15–$15/mg; 40 mg “bulk” format (Aminoclub, Disguised Alpha) compressing toward $1–3/mg in 2026. No MOTS-c-specific vendor scandal on the scale of recent retatrutide underdosing events surfaced in this pass.

Community Score: 47 / 100 (Usage 14/25; Codification 11/25; Effect consistency 9/25; Time-in-circulation 13/25). Mid-tier niche — well above genuinely fringe (FOXO4-DRI, SHLP2), well below universal staples (BPC-157, TB-500, GLP-1s, epitalon).

8. Safety Profile

Phase 1a/1b clinical (CB4211, n ≈ 85 total) ⚠️: “Well-tolerated, no SAEs”; only >10% AE in Phase 1b was transient mild-to-moderate injection-site reaction. No peer-reviewed safety publication; data are press-release + AASLD poster only.

Native MOTS-c human safety data: None published. Community-reported AEs (injection-site burning/welts, occasional hematoma, single-source-loud anaphylaxis warning, head-spin at ≥5 mg, post-pin lethargy) are not characterised in peer-reviewed form.

Trial exclusions in CB4211 Phase 1b: T2D, pregnancy, lactation, chronic conditions.

Theoretical safety concerns:

• Long-term consequences of chronic systemic AMPK activation not characterised in humans for any indication (metformin is an incomplete reference because of non-AMPK actions)
• Theoretical immunogenicity from chronic dosing of a normally-intracellular endogenous peptide; no ADA data
• Ambiguous effects on cell-survival pathways under glucose restriction in cancer cell lines
• AMPK-mTOR opposition flagged in community as a hypertrophy-blunting concern; no human study addresses this

Special populations: No data — pregnancy, lactation, paediatrics, hepatic/renal impairment, mtDNA disease.

Long-term safety: Unknown beyond 4 weeks of CB4211 dosing.

Retraction status: No retractions of primary MOTS-c research identified. A 2024 review corrigendum [PMC10963594] retracted a single “gold-standard” assertion regarding LC/MS detection (see 7.5).

Community-reported AEs requiring science-layer attention:

1. Anaphylaxis — single-source-amplified, no clinical literature; cannot be evaluated.
2. Anaphylaxis-tier injection-site reactions at higher doses — widespread report, no clinical characterisation.
3. Folate-methionine cycle “crash” — community-theorised, mechanistically plausible per Lee 2015 preclinical pathway, never characterised in humans.

9. Drug Interactions

• Metformin — theoretical additive/redundant AMPK activation; clinical significance unknown
• AICAR / direct AMPK activators — theoretical additive (AICAR is itself WADA-prohibited under S4.4.1)
• SGLT2 inhibitors — mechanistic adjacency in nitrosative-stress modulation; uncharacterised
• GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) — overlapping insulin-sensitisation and weight-loss profile; no interaction data; community stacks routinely
• Exercise — endogenous MOTS-c rises with acute and chronic training; pharmacodynamic overlap with administered MOTS-c plausible but uncharacterised
• CYP / transporter interactions — peptide pharmacology; not anticipated

10. Research Gaps

1. No Phase 2 or Phase 3 trial of native MOTS-c or any analog. CB4211 program discontinued at Phase 1.
2. No active sponsor since CohBar dissolution 2023.
3. No validated commercial ELISA with mass-spec confirmation of endogenous human plasma MOTS-c — Knoop & Thevis 2019 raises unresolved assay-validity concerns propagating through every observational human “MOTS-c level” study.
4. No replication of m.1382A>C exercise-capacity / longevity association outside East Asian cohorts (variant absent elsewhere).
5. Proximal molecular target ambiguity — AMPK vs CK2 vs TRIM72 vs nuclear DNA; direct vs indirect activation unresolved.
6. Cellular uptake of exogenous cationic 16-aa peptide unclear.
7. No PK/PD characterisation in peer-reviewed form for native MOTS-c or CB4211.
8. No long-term safety data beyond 4 weeks CB4211.
9. No head-to-head vs metformin, GLP-1RAs, or exercise alone for metabolic endpoints.
10. Single-group dependency 🔴 on USC Cohen laboratory for mechanism-defining studies.
11. Regulatory pathway unclear — PCAC 23 July 2026 vote determines 503A compounding access, not drug approval; FDA-evaluated uses (“obesity and osteoporosis”) are narrower than popular-press indications.

11. Bottom-Line Encyclopedia Note

MOTS-c is a 16-amino-acid peptide (MRWQEMGYIFYPRKLR; ~2,174 Da) encoded within the mitochondrial 12S rRNA gene, identified by the Cohen laboratory at USC in 2015. Preclinical evidence — primarily in rodent metabolic, exercise, bone and cardiovascular models — supports an exercise-mimetic, insulin-sensitising, AMPK-related profile, though the proximal molecular target remains contested (folate-AICAR-AMPK vs CK2 vs TRIM72). The only interventional human data come from a single Phase 1a/1b industry-sponsored trial of the analog CB4211 in obese NAFLD subjects (n = 20 in Phase 1b), reported by press release with no peer-reviewed publication; the sponsor (CohBar) dissolved in 2023 and no successor program exists. MOTS-c is not approved by any regulatory authority worldwide, is prohibited at all times by WADA under S4.4.1 (AMPK activators), and is scheduled for FDA Pharmacy Compounding Advisory Committee review on 23 July 2026 for potential 503A inclusion under “obesity and osteoporosis.”

11B. Gap Analysis — Where Science and Community Diverge

Topic	Science Layer	Community Layer	Gap
Native MOTS-c efficacy in humans	Zero interventional data. All published human data are observational biomarker measurements of endogenous MOTS-c, none involving administration.	Multiple positive subjective reports across MESO-Rx threads; energy, fasted-cardio HR, fat-loss claims	🔴 MAJOR GAP — community is reporting effects of a substance that has never been tested in humans interventionally. “Untested,” not tested-negative or tested-mixed. The CB4211 Phase 1b is a different molecule.
CB4211 liver-fat endpoint	Imaging endpoint failed — liver fat MRI-PDFF reduction was identical to placebo (−5.03% vs −4.88%, NS). Only ALT/AST/fasting-glucose moved on press-release exploratory analysis ⚠️	Community treats CB4211 topline as “positive” and as supporting the native peptide	Community misreads the only completed clinical trial — relies on ALT/AST/glucose framing without registering that the prespecified imaging endpoint did not separate from placebo.
Dosing	Animal dose ~15 mg/kg IP — non-translatable. CB4211 used 25 mg SC daily. No native-peptide PK/PD published.	Two competing schools: 1–2 mg/day vs 5–10 mg 1–2×/wk. No convergence. Greenfield’s ≥10 mg/injection routinely questioned within the community itself.	Community openly admits no anchor exists — neither layer has a defensible human dose for the native peptide. Closest alignment between layers, paradoxically because both layers acknowledge ignorance.
Mechanism — proximal target	Unresolved: AMPK vs CK2 vs TRIM72. Single-group dependency 🔴 on most claims. Direct vs indirect AMPK activation unresolved.	Community defaults to “AMPK activator” framing; Necessary Evil’s AMPK-vs-mTOR critique is rare sophistication.	Community simplifies a scientifically contested target story into a single-mechanism framing. The AMPK-mTOR opposition the community surfaces is real per Lee 2015 mechanism — but unevaluated for hypertrophy outcomes.
Anaphylaxis	Not characterised. Theoretical immunogenicity concern only; no anti-drug-antibody data.	Loud “carry an EpiPen” warning since Feb 2026 (Proud Pangolin), widely repeated; one user reported feeling “weird” after accidental 8 mg dose.	Community-only signal that science cannot evaluate. Cannot be dismissed (16-aa cationic peptide is biologically plausible immunogen) and cannot be confirmed. Single-source amplification dynamics apply.
Injection-site burning / welts	Phase 1b reported “transient mild-to-moderate injection-site reactions” >10% ⚠️ — no characterisation of severity in published form.	Widespread; “crazy burning sensation” routinely reported; subcutaneous hematoma thread exists.	Aligned in direction, community fills detail science omitted.
Tachyphylaxis	Not studied — no chronic-dosing human exposure data.	Common report: “first two weeks were crazy, tapered off.”	Community-only observation that science has no data to address.
Folate-methionine cycle effects in humans	Preclinical mechanism in Lee 2015 (folate-AICAR-AMPK indirect activation 🔴). No human PD/safety data.	Necessary Evil’s methylfolate-cofactor protocol architecture; Nattybynature reports no crash at 12 mg/wk without methylfolate.	Community has invented mitigation for a preclinical mechanism that may not translate to humans at community doses. Untestable until human PD studies exist.
Single-lab dependency 🔴	Explicitly flagged: Lee/Cohen group dominates mechanism papers; “independent” replications (Auckland) share authorship.	Largely unaware. Community cites “the studies” without group attribution.	Community accepts the single-group risk that science flags.
WADA S4.4.1 prohibition	Explicit, with named USADA advisory.	Not a foreground concern — community is recreational and PED-tolerant; no athlete-protection register.	Aligned absence rather than gap — community knows but doesn’t care; users in tested sport contexts would need explicit advisory.
PCAC July 2026 vote and 503A pathway	Foregrounded — defines compounding-pharmacy access trajectory.	Largely unaware; vendor landscape stable in May 2026.	Science-layer foresight not yet community-relevant — vote outcome will be the bigger gap-closer.
Detection assay validity (Knoop & Thevis)	Unresolved methodological dispute (ELISA vs LC/MS); 2024 corrigendum retracted “gold-standard” framing.	Not discussed.	Community is unaware that the observational literature underpinning many “MOTS-c levels in X disease” claims is methodologically contested.
CohBar dissolution	Documented and foregrounded; no successor sponsor since 2023.	Vendor and biohacker-blog ecosystem continue marketing as if research is ongoing.	Commercial narrative outlives the scientific program.

Net characterisation. MOTS-c sits in the community-ahead-of-science / hyping-noise cell of the gap matrix, subclassified “untested” — not tested-negative, not tested-mixed. This is the most distinctive feature of the compound: the community has constructed a protocol literature, vendor landscape, stack culture, and subjective-effects vocabulary around a peptide that has never been administered to humans in a published interventional study. The one completed clinical trial used a different molecule (CB4211), failed its imaging endpoint, was published only by press release, and its sponsor has dissolved. The three highest-consequence gaps:

1. Community is reporting effects of a substance that has never been tested in humans interventionally. Every subjective effect report — energy, fasted-cardio HR, fat-loss — exists outside any controlled human evaluation of the native peptide.
2. Community misreads the CB4211 trial as proof of the underlying compound while the trial’s imaging endpoint did not separate from placebo.
3. The anaphylaxis warning circulating in community sources is unevaluable in either direction by current science.

12. Three Paths

You choose your risk tolerance. This monograph provides the data, not the recommendation.

Conservative path — wait. Defined as not engaging until at least one of: (a) peer-reviewed publication of any completed interventional trial of native MOTS-c in humans; (b) regulatory approval somewhere; (c) independent (non-Cohen-lab) Phase 2 RCT of native MOTS-c; (d) validated mass-spec confirmation of endogenous circulating MOTS-c resolving the Knoop & Thevis 2019 methodological dispute. None of the four gates are met as of 14 May 2026. The PCAC 23 July 2026 vote does not change this — 503A inclusion is a compounding-eligibility decision, not drug approval and not a clinical-efficacy verdict.

Moderate path — Tier C with monitoring. Defined as treating native MOTS-c as preclinical-only with one indirectly-relevant Phase 1 program (CB4211) and accepting all the gaps named in 11B. This path requires: full pre-cycle baseline bloodwork (lipid panel, HbA1c, fasting glucose, ALT/AST/GGT, lipase, BMP, TSH, resting HR/BP, body composition); awareness that no human dose anchor exists for the native peptide; selecting the lower-dose-daily school (1–2 mg SC, pre-fasted cardio) rather than the high-dose-Greenfield school; capping at 5 mg/wk total exposure; one cycle of 4–6 weeks with on-cycle bloodwork at week 3; off-cycle 4 weeks before any second cycle; methylfolate co-administration as community-theoretical mitigation (low-cost, no downside); explicit awareness of WADA S4.4.1 status for anyone in tested sport.

High-tolerance path — grey-market with mitigation. Defined as acknowledging that none of the conservative gates are met, that the community is reporting effects of an untested substance, that the one completed trial used a different molecule and failed its imaging endpoint, that the anaphylaxis signal cannot be evaluated, and that the supply chain is entirely “research-chemical.” The community mitigation stack documented here: third-party COA verification (Janoshik, Freedom Diagnostics) of the specific vial; preference for vendors that publish labelled-vs-actual mass per batch (Aminoclub model); titration starting at 1 mg SC and observing 72 h before incrementing; capping below 5 mg per single injection (community “head spin” threshold); on-hand EpiPen access for the first three injections (community-defensive, not science-derived); structured bloodwork; physician-monitoring dialogue even where prescription is not available.

13. Key References

Scientific:

Discovery / mechanism:

• Lee C et al. Cell Metab 2015;21(3):443–454 — discovery, PMID 25738459 🔴 [Peer-reviewed human + preclinical]
• Kim KH, Son JM, Benayoun BA, Lee C. Cell Metab 2018;28(3):516–524 — nuclear translocation, PMID 29983246 🔴
• Cobb LJ et al. Aging (Albany NY) 2016;8(4):796–809 — MDP cataloguing, PMID 27070352
• Kumagai H, Kim S-J et al. iScience 2024 — CK2 direct target, PMID 39561759 🔴
• Jia H et al. Theranostics 2024;14(13) — TRIM72/membrane repair, PMID 39239515 (independent)

Exercise / physical performance:

• Reynolds JC et al. Nat Commun 2021;12:470 — exercise-induced regulator, PMID 33473109 🔴
• D’Souza RF et al. Aging (Albany NY) 2020;12(6):5244 — muscle myofibre association, PMID 32218446
• Yuan J et al. Sci Rep 2021;11:20077 — rat cardiac mechanical efficiency, PMID 34635705
• Wrzosek M et al. Int J Mol Sci 2023;24(19):14951 — muscle-strength correlation, PMID 37958833
• Dieli-Conwright CM et al. Sci Rep 2021;11:16916 — breast-cancer-survivor exercise RCT secondary analysis, PMID 34413414

Genetic / population:

• Zempo H, Kim S-J, Fuku N et al. Aging (Albany NY) 2021;13(2):1692–1717 — m.1382A>C, PMID 33468709

Disputed methodology:

• Knoop A, Thomas A, Thevis M. Rapid Commun Mass Spectrom 2019;33(4):371–380 — LC/MS detection failure in unspiked plasma, PMID 30394592
• Gruschus JM et al. Sci Rep 2023;13:14110 — codon-bias evidence, PMID 37644062
• Corrigendum 2024 — PMC10963594 — gold-standard sentence retraction

Industry / regulatory:

• CohBar press release 10 August 2021 — CB4211 Phase 1a/1b topline ⚠️
• CohBar 8-K filed 1 November 2023 — termination of merger / dissolution
• FDA Advisory Committee Calendar — PCAC 23–24 July 2026, Docket FDA-2025-N-6895
• WADA 2026 Prohibited List — S4.4.1
• USADA “What is the MOTS-c peptide?” athlete advisory

Community:

• MESO-Rx threads: “Mots-C” (Aug 2025); “My MOTS-c Run: 5-Week Ramping Protocol” (Feb 2026, 48 replies); “MOTS-C & SS-31????” (Apr–May 2026, 51 replies); “Mots-C Hematoma” (Oct 2025)
• AnabolicMinds “Ever hear of the Peptide MOTS-c?” — earliest peptide-forum mention
• Ben Greenfield “Wolverine Peptide Stack” + “What Are Peptides” podcast — anti-aging stack anchor
• Vigorous Steve — “Safest & Best Mots-C Dosing Protocols” YouTube; “Mots-C Deep-Dive Addendum LIVE” (IMDb tt36685060, 24 April 2025); “The ULTIMATE ‘No Stimulants’ Fat Burner Stack” podcast
• Modern Healthspan YouTube — Pinchas Cohen episode series (Cohen does not endorse community protocols)
• Vendor pages cited: Peptide Sciences, Aminoclub (COA-transparent), Limitless Life, BioLongevity, Peptide Partners, Verified Peptides, Pharma Lab Global (pre-mixed pen)
• Swolverine “MOTS-c For Beginners” — representative fitness-blogosphere reinforcement
• Dr. Iman Bar — clinician-branded protocol page

14. Audit / Refresh Trail

• Composed: 14 May 2026
• Next refresh triggers:
  • PCAC vote 23–24 July 2026 — outcome decides 503A compounding pathway for “obesity and osteoporosis”
  • Any new sponsor announcement for CB4211 or native MOTS-c clinical development
  • First peer-reviewed publication of CB4211 Phase 1a/1b data
  • Any registered Phase 1 or Phase 2 interventional trial of native MOTS-c
  • Validated mass-spec confirmation resolving the Knoop & Thevis assay dispute
  • WADA 2027 Prohibited List update (annual; check December 2026)
  • Any vendor scandal or COA-fraud event affecting the MOTS-c supply chain
  • Mainstream-podcast adoption (Huberman / Attia / Sinclair episode) — currently absent
  • Direct r/Peptides / r/Biohackers thread retrieval to close the community-source retrieval gap on Reddit (current corpus is MESO-Rx-heavy)

15. Comparative-table note

New class identified: Mitochondrial peptides — MOTS-c, Humanin, SS-31/elamipretide, SBT-272. Action: Create comparative_mitochondrial_peptides_YYYY-MM-DD.md once a second compound in this class is composed under the encyclopedia. The community-layer data already signals SS-31 (elamipretide) as the obvious second compound: the dominant 2026 community stack is MOTS-c + SS-31, with a dedicated MESO-Rx thread (51 replies / 1K views, April–May 2026) explicitly comparing the two, and Vigorous Steve podcast content on “SS-31 & Mots-C Synergy.” SS-31 is the natural next compound for this class. Fields the eventual class row will affect: WADA status (MOTS-c S4.4.1; SS-31 status to be confirmed); FDA approval status (MOTS-c unapproved, pending July 2026 PCAC; SS-31 has a more developed regulatory file with Phase 3 history); primary indication (MOTS-c “obesity and osteoporosis” per FDA; SS-31 mitochondrial myopathy / Barth / ischaemia-reperfusion); evidence tier; community dose range; mechanism (mitokine vs SS peptide cardiolipin binder); CohBar/Stealth Bio sponsor status; community-Score band.